Resolution of menstrually related migraine following aggressive treatment for breast cancer.
Hormonal influences associated with the female menstrual cycle play strong roles in both migraine and particular types of breast cancer, but there is limited literature on the effects of breast cancer treatment regimens in women with migraine. The present case describes resolution of menstrually related migraine following aggressive treatment for infiltrating ductal carcinoma (neoadjuvant chemotherapy, single radical mastectomy, and locoregional radiation therapy) that was maintained with supplemental treatment using tamoxifen, an anti-estrogenic agent. This novel case is presented to stimulate further research into the hormonal mechanisms underlying migraine.
Smitherman
Todd A
TA
Department of Psychology, University of Mississippi, Oxford, MS 38677, USA.
Kolivas
Elizabeth D
ED
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D004967:Estrogens / Q000378:metabolism; D005260:Female; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects / Q000502:physiology; D008599:Menstruation Disturbances / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D008881:Migraine Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D017239:Paclitaxel / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology* / Q000627:therapeutic use; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D017239:Paclitaxel